• Staff Writer

Researchers in Mexico Profile Molecular Markers with Potential to Predict Diabetes Complication

In a recent peer-reviewed publication appearing in BMJ Open Ophthalmology, researchers in Mexico describe serological cytokine profiles with significant statistical correlation to diabetic retinopathy (DR), a complication of type 2 diabetes (DM 2).


Image: C. Deluvio

Incidence of type 2 diabetes is disproportionally concentrated and irregularly distributed across racial and ethnic minorities including Latinx and BIPOC populations in the United States. The findings by Jonathan Uriel Quevado-Martínez et al. (2021) suggest that further understanding of putative biomarkers may, "select [for] proper therapeutic targets for the treatment of diabetic retinopathy."


Read more at Pro-inflammatory cytokine profile is present in the serum of Mexican patients with different stages of diabetic retinopathy secondary to type 2 diabetes | BMJ Open Ophthalmology.



Part of health disparities news and research reporting by North Carolina Health Equity Project, Inc. Image credits: Charles Deluvio and Anthony Metcalfe on Unsplash. The views expressed by the authors of any cited publication(s) or external link(s) do not necessarily reflect the views of North Carolina Health Equity Project, Inc., nor are any affiliations or endorsements implied.

 

The Mission and Vision of North Carolina Health Equity Project, Inc.

North Carolina Health Equity Project, Inc., NCHEALTHEQ™, develops adaptive, intelligent, next-generation technologies to improve health outcomes for all people, especially those in marginalized communities. We leverage the power of cross-disciplinary innovation and disruptive technologies including AI/ML, “accelerating research and saving lives.” Learn more at https://www.nchealtheq.org/.


Contact Us

Corporate and Governmental Affairs

North Carolina Health Equity Project, Inc.

mail@nchealthequity.org

+1 336-283-5094


NCHEALTHEQ™ is a trademark of North Carolina Health Equity Project, Incorporated ("NCHEP"). Governance | Terms | Privacy © 2021, NCHEP or its affiliates.



26 views0 comments